KalVista Pharmaceuticals Inc

KalVista’s FDA‑approved oral drug Ekterly gives hereditary angioedema patients a fast, self‑administered break‑out therapy, positioning the company to capture rising global demand amid intensifying competition.

KalVista Pharmaceuticals, Inc. is a beacon of innovation and hope in the biotechnology sector, dedicated to developing small molecule protease inhibitors to treat diseases with significant unmet needs.